WallStSmart

AbbVie Inc (ABBV)vsSonida Senior Living Inc (SNDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 18081% more annual revenue ($61.16B vs $336.39M). ABBV leads profitability with a 6.9% profit margin vs -21.0%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.7Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

SNDA

Avoid

27

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 4.7Quality: 2.5
Piotroski: 2/9Altman Z: -0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-29.3%)

Margin of Safety

-29.3%

Fair Value

$163.42

Current Price

$211.32

$47.90 premium

UndervaluedFair: $163.42Overvalued

Intrinsic value data unavailable for SNDA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$360.63B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4810/10

Growing faster than its price suggests

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
34.1%10/10

Strong operational efficiency at 34.1%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

SNDA0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
6.9%3/10

6.9% margin — thin

P/E RatioValuation
100.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-88.7%2/10

Earnings declined 88.7%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

SNDA4 concerns · Avg: 3.3/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Market CapQuality
$1.79B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.8%3/10

Operating margin of 2.8%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.

Bull Case : SNDA

Revenue growth of 12.0% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.

Bear Case : SNDA

The primary concerns for SNDA are PEG Ratio, Market Cap, Operating Margin. Debt-to-equity of 8.45 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABBV profiles as a value stock while SNDA is a turnaround play — different risk/reward profiles.

SNDA carries more volatility with a beta of 0.75 — expect wider price swings.

SNDA is growing revenue faster at 12.0% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (63/100 vs 27/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Sonida Senior Living Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Sonida Senior Living, Inc. develops, owns, operates and manages senior living communities in the United States. The company is headquartered in Dallas, Texas.

Want to dig deeper into these stocks?